The Cost Effectiveness Analysis of PD-1 And PD-L1 Agents Compared with Docetaxel for Second-Line Treatment of Advanced Non-Small Cell Lung Cancer

May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.191
https://www.valueinhealthjournal.com/article/S1098-3015(18)30491-1/fulltext
Section Title :
Section Order : 1044
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30491-1&doi=10.1016/j.jval.2018.04.191
HEOR Topics :
Tags :
Regions :